The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan
Abstract
The powerful demographic trend toward aging of populations in most countries has appropriately focused attention on the health problems of older men. Although there is agreement that serum total, bioavailable, and free testosterone concentrations decline with advancing age (Haffner et al, 1996; Kaufman and Vermeulen 1997; Morley et al, 1997; Zmuda et al, 1997; Smith et al, 2000; Harman et al, 2001), there is considerable uncertainty about the benefits and risks of testosterone replacement in older men with low testosterone concentrations (Bhasin and Buckwalter 2001; Matsumoto 2002). Initial randomized, placebo-controlled studies (Tenover 1992, 1998; Morley et al, 1993; Sih et al, 1997; Snyder et al, 1999a,b; Urban 1999; Kenny et al, 2001) have established the feasibility of testosterone replacement in older men for up to 3 years, and demonstrated that testosterone replacement increases fat-free mass, sense of well-being, and bone mineral density, and decreases fat mass in older men with low or low-normal testosterone concentrations. However, these initial studies (Tenover 1992, 1998; Morley et al, 1993; Sih et al, 1997; Snyder et al, 1999a,b; Urban 1999; Kenny et al, 2001) were neither designed to determine the effects of testosterone supplementation on health outcomes such as fracture rates, falls, physical function, disability, neurocognitive ability, and progression to dementia, nor powered to evaluate the effects of androgen administration on prostate and cardiovascular event rates. Long-term studies of 1 to 3 years in duration (Sih et al, 1997; Tenover 1998; Snyder et al, 1999a,b; Kenny et al, 2001) have generally reported a greater increase in hematocrit with testosterone administration than that associated with placebo administration. A few older men will develop hematocrits >55% during testosterone administration; increases in hematocrit to these high levels would increase blood viscosity, decrease blood flow rates, and might increase the risk of stroke. Androgen replacement may also worsen or induce sleep apnea, and cause edema, especially in older men with pre-existing heart disease. In the context of this uncertainty about the long-term risks of testosterone supplementation in older men, it is notable that testosterone prescription sales have increased 1700% in the last 9 years, and have grown 460% just in the last 3 years. Testosterone sales that had been stagnant at about $18 million until 1988 are projected to reach $400 million before the end of 2002 (IMS sales data, Philadelphia, Pa; BMC Corporation sales data, Minne-apolis, Minn). Whereas the greatest growth in testosterone sales appears to be in men with hypogonadism and younger than 65 years of age, testosterone use is also growing in older men. A growing interest in testosterone use is reflected in greater media and public attention that this topic has received. Although prostate event rates have not been significantly different between placebo- and testosterone-treated men in the previously published studies of testosterone replacement in older men (Sih et al, 1997; Tenover 1998; Snyder et al, 1999a,b), it is important to recognize that these studies did not have sufficient power to detect significant differences in prostate event rates between the 2 groups. It has been estimated that in order to detect a 30% difference in prostate cancer incidence rates between the placebo- and testosterone-treated groups, it would require randomization of approximately 6000 older men with low testosterone levels to the placebo and testosterone groups and treatment for an average of 5 years. Because such a randomized clinical trial would likely include relatively healthy older men with unequivocally low testosterone levels who do not have prostate cancer or prostate-specific antigen (PSA) levels >4 ng/mL, this would require screening a significantly larger number of older men in order to enroll 6000 eligible men. Accrual of sufficient numbers of men in such a clinical trial would be a challenging task. At this time, no study of this size has been funded; therefore, we will not know for several years whether testosterone replacement increases the incidence of clinically overt prostate cancer. Because the baseline prevalence of benign as well as malignant prostatic disorders is high (Berry et al, 1984; Carter et al, 1990; Sakr et al, 1994; Coley et al, 1995; Hsing et al, 2000; Jemal et al, 2002) in older men and the risks of prostate problems during testosterone administration remain undefined, there is understandable anxiety among health care providers who are facing increasing pressure from patients to consider hormone replacement. Therefore, the objectives of this commentary are to review the available data on the effects of testosterone replacement on the risk of prostatic disease in older men, and to present some recommendations for prostate monitoring during androgen administration in older men. This review should not be construed as our endorsemen
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationMcConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Self-citationMorley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., Morley, P. M. K., Stauber, P. M., Vellas, B., Baumgartner, R. N., & Garry, P. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90057-3 · Cited by 830
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791
Prospective Study of Sex Hormone Levels and Risk of Prostate Cancer
Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C., & Stampfer, M. J. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.16.1118 · Cited by 782
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis
Urban, R. J., Bodenburg, Y. H., Gilkison, C., Foxworth, J., Coggan, A. R., Wolfe, R. R., & Ferrando, A. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.5.e820 · Cited by 608
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531
Andropause: clinical implications of the decline in serum testosterone levels with aging in men
Matsumoto, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.2.m76 · Cited by 490
Effects of Testosterone Replacement in Hypogonadal Men
Snyder, P. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2670 · Cited by 464
Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460
Kenny, A. M., Prestwood, K. M., Gruman, C. A., Marcello, K. M., & Raisz, L. G. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.5.m266 · Cited by 456
Wang, C. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2839 · Cited by 359
Haffner, S. M., Shaten, J., Stem, M. P., Smith, G. D., Kuller, L., & MRFIT Research Group (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008832 · Cited by 320
Morales, A., & Lunenfeld, B. (2002) · The Aging Male · doi:10.1080/tam.5.2.74.86 · Cited by 266
Smith, K. W., Feldman, H. A., & McKinlay, J. B. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01152.x · Cited by 203
Declining gonadal function in elderly men
Kaufman, J. M., & Vermeulen, A. (1997) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(97)80302-3 · Cited by 181
Wayne Meikle, A., Arver, S., Dobs, A. S., Adolfsson, J., Sanders, S. W., Middleton, R. G., Stephenson, R. A., Hoover, D. R., Rajaram, L., & Mazer, N. A. (1997) · Urology · doi:10.1016/s0090-4295(96)00445-1 · Cited by 125
Cited by
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
“6 ng/ml shouldbe followedusinga standardized,monitoring plan (Table 8) to facilitate early detection of adverse events and to prevent unnecessary prostate biopsies that might lead to detectionofsubclinicalprostatecancer(77,98).”
BackgroundSelf-citationTestosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Self-citationAdvances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citation
Metadata
- Authors
- Bhasin, S., Singh, A. B., Mac, R. P., Carter, B., Lee, M. I., & Cunningham, G. R.
- Venue
- Journal of Andrology
- Publisher
- Wiley
- Published
- 2003-05-06
- Volume
- 24
- Issue
- 3
- Pages
- 299-311
- ISSN
- 0196-3635 (ISSN-L)
- 1939-4640
- OpenAlex
- W2165312445
- Cited by
- 221
- References
- 22
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.